SWAP: Adding or Switching to PegIFN Improves Response in Patients With Chronic Hepatitis B on Long-Term NA Therapy

November 8-12, 2019; Boston, Massachusetts
Patients on stable nucleos(t)ide analogue therapy who added or switched to pegIFN had significantly better HBeAg loss rates and HBsAg level reductions compared with patients who continued nucleos(t)ide analogue therapy alone.
Format: Microsoft PowerPoint (.ppt)
File Size: 186 KB
Released: November 16, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

Dr Graham Foster on optimizing management of HBV in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: January 17, 2023

Dr Maria Buti shares strategies to ensure patients with HBV are promptly screened for HDV, from Clinical Care Options (CCO)

Maria Buti, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 12, 2023 Expired: January 11, 2024

Download this slideset on overcoming barriers in HDV screening, from Clinical Care Options (CCO)

Maria Buti, MD Released: January 5, 2023

Learn from Dr Nancy Reau why we may want to challenge current guidelines on HDV screening, from Clinical Care Options (CCO)

Nancy Reau, MD Released: January 5, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings